Search results
Showing 376 to 388 of 388 results for infection control
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making
This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods
Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults.
Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.
The NICE public health guidance development process (third edition) (PMG5)
The NICE public health guidance development process (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection
- 3 The guidance development processes
- 4 The role of stakeholders in the guidance development process
- 5 The role of the Public Health Advisory Committees (PHACs) in the development of public health guidance
- 6 The role of evidence providers
- 7 The role of the CPHE project team
- 8 Fieldwork
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
NICE draft guidance recommends novel treatment for debilitating inherited skin condition
Around 670 people in England with painful and debilitating skin wounds caused by a rare inherited disorder are set to benefit from a new treatment to help the skin wounds heal faster.
Updated tuberculosis guidelines will help target most vulnerable
Updated tuberculosis (TB) guidelines call for greater education and prevention to help target people from socially deprived backgrounds who are most vulnerable to contracting the infection.
The NHS is being urged to tackle the rise in antibiotic resistance by cutting back on unnecessary use of the drugs.
NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.
Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE today (Tuesday, 12 April 2022) published draft guidance estimating their value to the NHS.
Good management of antibiotics can halve the number of people picking-up drug-resistant infections in hospital, new data suggests.
Use paracetamol to relieve a sore throat rather than antibiotics
The majority of sore throats do not need antibiotics and medicated lozenges may only help to reduce pain by a small amount, NICE says.